The Australian Translational Breast Cancer Research Symposium 2020 is a one of a kind event in the research meeting calendar.
Its objective is to bring together the Australian breast cancer research community, spanning basic researchers and clinicians, for one day of updates in cutting edge translational breast cancer research.
The plenary speakers for the 2020 meeting Ciara Metcalfe (Genentech), Geoff Lindeman (WEHI), and Sarat Chandarlapaty (MSK). We have also assembled a national faculty of key leaders in breast cancer research.
Registrations are limited to 350 places; and are kindly supported by our generous sponsors.
We encourage researchers and clinicians of all stages of their careers to join us.
Symposium details
Date
- 12th March 2020
Venue
- The Auditorium,
Garvan Institute of Medical Research,
384 Victoria St, Darlinghurst NSW 2010 - Entry via Burton St
Cost
- Free.
Organising Committee
- Elgene Lim, Alex Swarbrick, Neil Portman and Simon Junankar.
Contact
- Simon Junankar: s.junankar@garvan.org.au
Speakers
Ciara Metcalfe (Genentech)
Geoff Lindeman (WEHI)
Sarat Chandarlapaty (Memorial Sloan Kettering)
Theresa Hickey (Adelaide Uni)
Peter Simpson (UQ)
Neil Portman (Garvan)
Belinda Parker (PMCC)
Joanna Achinger-Kawecka (Garvan)
Georgia Chenevix-Trench (QIMR)
Kaylene Simpson (PMCC)
Shom Goel (PMCC)
Liz Caldon (Garvan)
David Croucher (Garvan)
Melissa Davis (WEHI)
Delphine Merino (ONJCRI)
Michael Samuel (CCB)
Alex Swarbrick (Garvan)
Program
Please note that this program may be subject to change.
Thursday 12 March
9.00am: Welcome by Elgene Lim (Garvan) and Alex Swarbrick (Garvan)
Plenary 1:
9.10am: Sarat Chandarlapaty (Memorial Sloan Kettering) – Insights into resistance to combination endocrine therapy
Session 1: New insights into luminal breast cancer
Chairs: Davendra Segara (St Vincent’s) and Sandra O'Toole (Garvan)
9.40am: Theresa Hickey (Adelaide Uni) – Targeting the androgen receptor in breast cancer
10.00am: Neil Portman (Garvan) – Targeting the p53 pathway in Luminal Breast Cancer
10.20am: Joanna Achinger-Kawecka (Garvan) – 3-dimensional epigenome remodelling in treatment resistant breast cancer
10.40am: Liz Caldon (Garvan) – CDK2 inhibitors, a novel therapy for ER+ and TNBC
11.00am: Peter Simpson (UQ) – Novel insights into Lobular Cancers
11.20am-12.00pm: Lunch and networking
Plenary 2:
12.00pm: Ciara Metcalfe (Genentech) – New hormone receptor-directed therapies for breast cancer
Plenary speakers
Ciara Metcalfe
Senior Scientist, Translational Oncology
Ciara leads the Selective ER Degrader program at Genentech and was the lead author on a publication on the mechanism of action of this class of drugs in Cell in 2019. Ciara began her scientific training at the University of the Witwatersrand in Johannesburg, South Africa, followed by graduate research at the MRC Laboratory of Molecular Biology at the University of Cambridge, UK. In 2010 she joined Genentech as a Postdoctoral Fellow, and then continued as a Scientist in Genentech’s Oncology Biomarker Department. Since 2015 she has led her own research group in the Translational Oncology department.
Professor Geoff Lindeman BSc(Med) MB BS(Hons) PhD FRACP FAHMS FAA
Joint Division Head of ACRF Cancer Biology and Stem Cells
Geoff is a clinician-scientist focusing on breast stem cell biology and translational breast cancer research. His laboratory, jointly headed with Professor Jane Visvader, is working to understand how normal and cancerous cells develop in the breast. They are using this information to advance new treatments for breast cancer. Geoff is the foremost translational breast cancer researcher in Australia, and currently leads international trials in targeting the apoptotic pathway in breast cancer, and prevention trials with denosumab in patients harbouring the BRCA1 and 2 mutations.
Sarat is a physician-scientist who undertook his physician training at Wake Forest School of Medicine and his PhD at University of North Carolina. His lab focuses on understanding the regulation of growth factor signal transduction pathways that are aberrantly activated in cancers, with a focus on those implicated in breast cancer pathogenesis. Sarat is a leader in deciphering the mechanisms of resistance to CDK4/6 inhibitors, drugs that have been revolutionising the treatment of advanced ER+ breast cancer.
